PERIOCHIP Drug Patent Profile

When do Periochip patents expire, and when can generic versions of Periochip launch?

Periochip is a drug marketed by Dexcel Pharma and is included in one NDA.

The generic ingredient in PERIOCHIP is chlorhexidine gluconate. There are fifty-eight drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Periochip

A generic version of PERIOCHIP was approved as chlorhexidine gluconate by BECTON DICKINSON on October 24^th, 1989.

Summary for PERIOCHIP

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	42
Clinical Trials:	5
What excipients (inactive ingredients) are in PERIOCHIP?	PERIOCHIP excipients list
DailyMed Link:	PERIOCHIP at DailyMed

Recent Clinical Trials for PERIOCHIP

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Dexcel Pharma Technologies Ltd.	Phase 3
Dexcel Pharma Technologies Ltd.	Phase 2

See all PERIOCHIP clinical trials

US Patents and Regulatory Information for PERIOCHIP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dexcel Pharma	PERIOCHIP	chlorhexidine gluconate	TABLET;DENTAL	020774-001	May 15, 1998		DISCN	Yes	No

Expired US Patents for PERIOCHIP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Dexcel Pharma	PERIOCHIP	chlorhexidine gluconate	TABLET;DENTAL	020774-001	May 15, 1998
Dexcel Pharma	PERIOCHIP	chlorhexidine gluconate	TABLET;DENTAL	020774-001	May 15, 1998

International Patents for PERIOCHIP

See the table below for patents covering PERIOCHIP around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	7480687
Austria	119391
Greece	3006681
Israel	86338
Israel	78826	PRECURSOR COMPOSITION FOR THE PREPARATION OF A BIODEGRADABLE IMPLANT FOR THE SUSTAINED RELEASE OF AN ACTIVE MATERIAL AND SUCH IMPLANTS PREPARED THEREFROM
Canada	1307463	COMPOSITIONS PHARMACEUTIQUES A LIBERATION PROLONGEE (SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS)
Japan	2960098

Market Dynamics and Financial Trajectory for PERIOCHIP: An Informed Analysis

Last updated: July 27, 2025

---

Introduction

PerioChip, an alloplastic periodontal drug device, has established itself within the niche of periodontal disease management. As a biodegradable chip containing chlorhexidine gluconate, it’s used as an adjunct in periodontal therapy to reduce bacterial load and promote healing. With increasing global periodontal disease prevalence and escalating demand for minimally invasive treatments, the market trajectory for PerioChip warrants a comprehensive analysis. This report examines the current market dynamics and forecasts future financial pathways, enabling stakeholders to make data-driven decisions.

---

Market Overview and Key Drivers

Global Burden of Periodontal Disease

Periodontal disease affects an estimated 35-50% of global populations, with severe cases impacting 10-15% [1]. The rising prevalence, driven by aging populations, tobacco use, poor oral hygiene, and systemic health links such as diabetes, fuels demand for effective periodontal therapies. These factors underpin a resilient demand for adjunctive treatments like PerioChip.

Regulatory Approval and Adoption

PerioChip received FDA clearance (1998) and subsequent approvals worldwide, facilitating its integration into periodontal treatment protocols. Regulatory endorsements enhance credibility, encourage dental practitioners’ adoption, and stabilize market penetration.

Technological Advancements

Innovations in drug delivery, biomaterials, and minimally invasive procedures bolster the efficacy and acceptance of local antimicrobial therapies. PerioChip’s biodegradable nature and sustained release profile align with current trends toward patient-friendly, outpatient procedures, enhancing its market appeal.

---

Market Dynamics Influencing PerioChip's Trajectory

Competitive Landscape

The periodontal therapeutics market is fragmented, with several options including local antimicrobial agents, systemic antibiotics, and mechanical debridement. Key competitors encompass products like Arestin (minocycline) and Atridox (doxycycline), which deliver antibiotics via different mechanisms.

PerioChip’s differentiation lies in its biodegradability, sustained release of chlorhexidine, and minimal side effects. However, competition from systems with broader-spectrum antibiotics and newer delivery platforms presents challenges to expanding market share.

Pricing and Reimbursement Policies

Pricing strategies significantly influence adoption rates. While PerioChip generally commands premium pricing due to its targeted delivery and convenience, reimbursement policies or lack thereof can limit utilization, especially in cost-sensitive markets. Health insurance and national healthcare systems’ reimbursement approvals are critical for wider acceptance.

Clinical Evidence and Guidelines

Robust clinical data demonstrating efficacy and safety foster practitioner confidence. Increasing integration of PerioChip into evidence-based guidelines for periodontal therapy supports consistent utilization growth.

Patient Acceptance and Oral Healthcare Trends

A shift towards minimally invasive, local treatments boosts patient preference for peri-implant and periodontal therapies using biodegradable chips. Awareness campaigns and dental professional education further accelerate acceptance.

---

Financial Trajectory: Past, Present, and Future Outlook

Historical Revenue Performance

While precise revenue figures are proprietary, available industry estimates suggest steady growth since market debut, driven by increased periodontal disease awareness and routine periodontal practice adoption. The global periodontal therapeutics market was valued at approximately USD 1.3 billion in 2021, with local drug delivery systems constituting a significant segment [2].

Growth Drivers and Barriers

Drivers:

• Increasing periodontal prevalence.
• Preference for minimally invasive treatments.
• Clinical guideline endorsements.
• Expansion into emerging markets with rising oral health awareness.

Barriers:

• High competition from alternative antimicrobial agents.
• Limited awareness in low-income regions.
• Regulatory procedures and reimbursement hurdles.

Projected Market Growth

Analysts project a compounded annual growth rate (CAGR) of approximately 6-8% for the local drug delivery segment in periodontal therapy over the next five years [3]. Assuming PerioChip’s current market share remains stable or slightly increases due to clinical validation and expansion, revenues could see an incremental rise of 10-15% annually.

Potential Revenue Streams

• Direct sales to dental practitioners.
• Collaborations with dental product distributors.
• Entry into emerging markets with unmet periodontal treatment needs.

Impact of Patent and Regulatory Landscape

Patent expirations or regulatory shifts could influence pricing flexibility and market exclusivity, impacting revenue streams. Currently, PerioChip’s patent protections prolong market dominance in certain jurisdictions, safeguarding profitability.

---

Strategic Opportunities and Risks

Opportunities

• Product Line Expansion: Developing combination therapies or modified-release formulations.
• Geographical Penetration: Targeting low- and middle-income countries with rising dental health awareness.
• Clinical Integration: Advocacy for inclusion in standard periodontal treatment protocols.

Risks

• Market Saturation: Fragmented market with prominent competitors.
• Regulatory Delays: Slower approval processes in emerging markets.
• Reimbursement Uncertainty: Financial barriers to adoption in certain healthcare systems.

---

Conclusion and Future Forecast

The financial trajectory of PerioChip appears optimistic within the growing periodontal therapeutics landscape. Its biodegradable, sustained-release profile positions it favorably amidst evolving minimally invasive treatment preferences. While competition remains intense, strategic positioning—through clinical validation, geographical expansion, and education—can enhance market share and revenue.

Stakeholders should monitor regulatory updates, clinical guideline incorporations, and emerging competitors to adapt their strategies accordingly. The combination of demographic trends, technological sophistication, and health-conscious consumer behavior underpin a pathway for sustained growth over the next five years.

---

Key Takeaways

• Growing Market Demand: Increasing periodontal disease prevalence drives demand for adjunctive localized drug therapies like PerioChip.
• Strategic Positioning: PerioChip’s biodegradable delivery system differentiates it, but competitive pressures necessitate innovation and marketing.
• Regulatory and Reimbursement Impact: Clearances and reimbursement policies significantly influence adoption and revenue potential.
• Expansion Opportunities: Emerging markets and product line extensions represent viable avenues for revenue growth.
• Conservative Forecast: A CAGR of 6-8% indicates steady, incremental growth aligned with broader trends in periodontal care.

---

FAQs

1. What are the primary factors influencing PerioChip’s market growth?
Rising periodontal disease prevalence, preference for minimally invasive treatments, clinical guideline adoption, and technological innovations drive growth, while competition and reimbursement policies pose challenges.

2. How does PerioChip compare to alternative periodontal therapies?
PerioChip offers a biodegradable, sustained-release antimicrobial that minimizes systemic side effects, appealing to practitioners seeking localized adjuncts. Alternatives like Arestin (minocycline) and Atridox (doxycycline) offer differing spectra and delivery profiles.

3. What barriers could impede PerioChip’s financial growth?
Market saturation, high competition, regulatory delays, limited awareness in certain regions, and reimbursement issues can restrict revenue expansion.

4. Which markets offer the most growth potential for PerioChip?
Emerging markets in Asia, Latin America, and Africa present significant growth opportunities due to rising oral health awareness, increasing disposable incomes, and unmet treatment needs.

5. How important is clinical evidence for PerioChip’s market success?
Highly critical; robust clinical data underpin guideline inclusion, practitioner trust, and insurance reimbursements, all vital for sustained adoption.

---

References

[1] World Health Organization. (2022). Global Oral Health Data.
[2] MarketsandMarkets. (2021). Periodontal Therapeutics Market Report.
[3] Grand View Research. (2022). Local Drug Delivery in Periodontal Therapy Market Forecast.